GURU - ETF AI Analysis
Top Page
Global X Guru Index ETF (GURU)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered strong gains so far this year, indicating solid recent results for investors.
Health Care Leadership
A large portion of the fund is in health care stocks, and several of its biggest biotech and pharma holdings have shown strong performance, helping drive returns.
Broad Sector Mix
Exposure across many sectors, including technology, industrials, consumer cyclical, financials, and utilities, helps spread risk across different parts of the economy.
Negative Factors
High Expense Ratio
The fund charges relatively high annual fees, which can eat into long-term returns compared with lower-cost ETFs.
Heavy U.S. Concentration
Almost all of the ETF’s holdings are in U.S. companies, offering very limited geographic diversification.
Mixed Performance Among Top Holdings
While several top positions have performed strongly, a few key holdings have shown weak or negative performance, which can drag on overall results.
GURU vs. SPDR S&P 500 ETF (SPY)
AUM63.68M
RegionNorth America
Expense Ratio0.75%
Beta0.99
IssuerGlobal X
Inception DateJun 04, 2012
Dividend Yield0.1%
Asset ClassEquity
Index TrackedSolactive Guru Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,078
30 Day Avg. Volume1,474
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
85.26Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering86
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GURU Summary
Global X Guru Index ETF (GURU) follows the Solactive Guru Index, which copies stock picks from well-known hedge fund managers based on their public filings. It holds a mix of U.S. companies across many sectors, with a big focus on health care and technology. Well-known names in the fund include United Airlines and Expedia. Someone might invest in GURU to get diversified exposure to the broader market while piggybacking on the research of professional investors. A key risk is that these stock picks can still be wrong, and the ETF’s value can go up and down with the stock market.
How much will it cost me?The Global X Guru Index ETF (Ticker: GURU) has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, aiming to replicate the strategies of top hedge fund managers rather than passively tracking a broad market index.
What would affect this ETF?The Global X Guru Index ETF (GURU) could benefit from positive trends in sectors like Health Care and Technology, which are heavily weighted in its portfolio and often driven by innovation and consumer demand. However, economic uncertainty, rising interest rates, or regulatory changes affecting hedge fund strategies could negatively impact the ETF's performance, as it relies on replicating hedge fund holdings primarily focused on U.S. markets. Investors should also consider the potential volatility in top holdings like Tesla and Alibaba, which are sensitive to global market conditions and sector-specific challenges.
GURU Top 10 Holdings
GURU is leaning heavily into U.S. health care, with a bench full of biotech and therapeutics names driving the story. Corcept Therapeutics and Apogee Therapeutics have been rising, giving the fund a helpful tailwind, while Astera Labs’ more mixed, recently lagging performance shows the tech side isn’t all smooth sailing. Immunovant and Kymera are steady-to-strong, adding to the fund’s momentum despite their financial growing pains. With most of its key bets in niche U.S. health care and select tech, GURU is clearly following hedge funds into higher-risk, higher-reward territory.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | 2.17% | $1.40M | $12.37B | 63.28% | 76 Outperform | |
| Apogee Therapeutics | 1.79% | $1.15M | $10.18B | 264.74% | 49 Neutral | |
| Natera | 1.69% | $1.09M | $44.67B | 94.96% | 73 Outperform | |
| Immunovant | 1.65% | $1.06M | $8.64B | 186.44% | 45 Neutral | |
| Expedia | 1.62% | $1.04M | $39.93B | 54.11% | 80 Outperform | |
| Astera Labs, Inc. | 1.56% | $1.01M | $55.79B | 71.74% | 68 Neutral | |
| Kymera Therapeutics | 1.54% | $994.41K | $9.76B | 178.34% | 56 Neutral | |
| Travere Therapeutics | 1.52% | $977.77K | $5.86B | 238.46% | 56 Neutral | |
| Caris Life Sciences, Inc. | 1.51% | $974.31K | $6.16B | -39.83% | 49 Neutral | |
| Driveway Vehicle Solutions | 1.49% | $962.00K | $8.30B | 21.32% | 76 Outperform |
GURU Technical Analysis
Positive
―
Price Trends
68.50
Positive
66.39
Positive
64.05
Positive
Market Momentum
0.69
Negative
59.98
Neutral
62.72
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GURU, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 68.85, equal to the 50-day MA of 68.50, and equal to the 200-day MA of 64.05, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 59.98 is Neutral, neither overbought nor oversold. The STOCH value of 62.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GURU.
GURU Peer Comparison
Comparison Results
Performance Comparison
GURU
Global X Guru Index ETF
70.44
14.25
25.36%
ABLD
Abacus FCF Real Assets Leaders ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
YALL
God Bless America ETF
―
―
―
PFOE
Pathfinder Focused Opportunities ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents